Singapore’s sector-wide platform AimSG hosts first AI-powered head CT scan

Every day, the Singapore General Hospital (SGH) performs about 50 head computed tomography (CT) scans, with about 10 per cent of these scans revealing acute brain bleeds that could be potentially life-threatening emergencies.

Rapidly identifying these haemorrhages and immediate medical interventions could make the difference between life or death for patients.

That’s where iScreen comes in, shared SGH’s Dr Sarat Kumar Sanamandra, who explained how this tool instantly analyses patients' head CT scans to spot signs of intracranial haemorrhage (ICH or brain bleeds) and automatically alerts radiologists to attend to urgent cases.

 iScreen helps prioritise cases needing immediate attention and treatment by delivering accurate artificial intelligence (AI) test results in around six minutes – which is an improvement on the usual 30 to 60 minutes for standard reporting, said Dr Robert Chen, Head and Senior Consultant, Department of Neuroradiology, Singapore General Hospital and National Neuroscience Institute (NNI@SGH).

iScreen was launched by SGH, national healthtech agency Synapxe, and healthtech startup Iota MedTech.

This AI software tool is the first head CT scan AI model deployed on AimSG, Singapore’s first and only national medical imaging platform, developed by Synapxe in partnership with NHG Health, National University Health System (NUHS) and SingHealth.

Since AimSG has been deployed across all three public healthcare clusters in eight public healthcare institutions, iScreen technology can be expanded to other public healthcare institutions, said Henry Kang, Director, Innovation Capabilities Enablement, DNAi, Synapxe.

Deployed once and accessible to all clusters

AimSG enables clinicians to obtain faster and more accurate diagnostic support by integrating AI into diagnostic imaging workflows across the local public healthcare ecosystem.

AimSG allows multiple AI models to be coordinated, managed and scaled across the public healthcare ecosystem, removing three key barriers: isolated software, vendor lock-in, and wasted effort on repetitive setups.

Once an AI model is deployed on AimSG, it is included in a central catalogue of AI models.

If a public healthcare institution or cluster wishes to use it, the model can be deployed with minimal additional installations or setup.

Since the platform’s launch in 2023, it has accelerated AI adoption across Singapore’s public healthcare imaging disciplines through seamless deployment, direct workflow integration, orchestration at scale, efficient model validation, and robust platform security.

Some of its deployments and AI models include: bone trauma interpretation, chest x-ray for tuberculosis screening, thyroid ultrasound, and head CT scan as the latest deployment.

DNAi’s Senior Manager, Kelvin Sng noted that Synapxe will continue to enhance the capabilities of the AimSG platform, increase the number of AI models, as well as scale the onboarding of hospitals across clusters.

iScreen’s impact

iScreen has been integrated to SGH’s radiology workflow since January 2026, with continued improvement in report turnaround times for CT brain scans, shared Dr Sanamandra.

Radiologists do not need to undergo any training to use it, which facilitated its integration to workflows.

Based on surveys with neuroradiologists and radiology residents at SGH, the results have shown that 87.5 per cent of respondents viewed the iScreen outputs routinely, with 93 per cent finding it useful.

73 per cent of respondents also noted that the automatic SMS alert helped them with prioritising cases, shared Dr Sanamandra.

In future, the team expects that iScreen will help over 18,000 patients at SGH and will support residents and junior radiologists to prioritise and interpret acute brain bleed cases.

“iScreen has shown that a locally developed AI solution can be successfully integrated into clinical practice, it can have high diagnostic performance, gain strong clinical acceptance and ultimately contribute to better patients’ outcomes,” said Dr Sanamandra.